ICE Bioscience Posters

Download

By combining the potency of payload with the specificity of antibody, antibody-drug conjugate (ADC) is an innovative and promising drug modality for cancer therapy, possessing the advantages of both chemotherapy and immunotherapy. As ADC development continues to advance, more novel types of payloads are being actively explored.

ICE Bioscience employs different screening approaches including biochemical, biophysical, cell-based, and LC/MS-based assays for payload screening and evaluation. To be specific, the methods for cytotoxic drug evaluations include microtubule polymerization assay, DNA topoisomerase I inhibition assay, different biochemical assays targeting DNA-damage response (DDR) pathways, and NMT1/2 FI assay. For degrader payloads, spectral shifts (SPS) or HTRF assays can measure binary/ternary complex formation, while HiBiT system and Western blot (WB) analysis are commonly used to quantify target degradation. For STING agonist/antagonist payload, ICE has ready-to-use assays for detecting STING binding, STING activation and cytokine release. Additionally, cell models—such as panels of various cancer cell lines, payload- or ADC-related drug-resistant cell lines, and 3D spheroids—along with immunogenic cell death (ICD) evaluation and ADME evaluation (particularly lysosome stability and permeability assays), are valuable for the evaluation of all payload types.